Barclays Reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Ponatinib Demonstrated Acceptable Safety Profile
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $25.78 --0%
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Barclays reiterates an 'Overweight' on ARIAD Pharmaceuticals (NASDAQ: ARIA) price target of $20.00.
Analyst, Ying Huang, said, "We attended the presentation of PACE trial data and ARIA management lunch at the annual meeting of American Society of Clinical Oncology (ASCO). We reiterate our rating as we become more confident in the FDA approval of ponatinib."
For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $15.63 yesterday.
Analyst, Ying Huang, said, "We attended the presentation of PACE trial data and ARIA management lunch at the annual meeting of American Society of Clinical Oncology (ASCO). We reiterate our rating as we become more confident in the FDA approval of ponatinib."
For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $15.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
- Benchmark Reiterates Buy Rating on Ooma (OOMA)
- Yum! Brands (YUM) PT Lowered to $180 at Argus
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
